Abstract:
An antibacterial substance which does not have optimum absorbability and is administered parentally into tissue, is administered to a host in conjunction with a benzylamine derivative of the formula ##STR1## wherein R 1  is hydroxyl in the 2- or 4-position or amino in the 2-position; 
     R 2  is hydrogen or alkyl of 1 to 3 carbon atoms; and 
     R 3  is cyclohexyl optionally substituted by hydroxyl; 
     or a non-toxic, pharmacologically acceptable acid addition salt thereof, to improve the absorption of the parenterally administered antibacterial substance.

Description:
This is a continuation-in-part of copending application Ser. No. 825,785, filed February 3, 1986, now U.S. Pat. No. 4,705,803; which in turn is a continuation of application Ser. No. 471,299, filed March 2, 1983, now abandoned. 
    
    
     FIELD OF INVENTION 
     This invention relates to a method of improving the absorption of injected antibacterial substances. More specifically, this invention relates to the use of benzylamine derivatives in combination with injected antibacterial substances to improve the absorption of said antibacterial substances after injection. 
     BACKGROUND OF THE INVENTION 
     It is known from the literature that benzylamine derivatives are useful as bronchosecretolytics in human and veterinary medicine. The best known examples of these benzylamine derivatives are N-(2-amino-3,5-dibromobenzyl)-N-methyl-cyclohexylamine hydrochloride (generic name: bromhexine) and N-(2-amino-3,5-dibromobenzyl)-trans-4-hydroxycyclohexylamine hydrochloride (generic name: ambroxol). These compounds produce a significant increase in the quantity of secretion, but it has been found that the viscosity of the secretion decreases and the concentration of solids in the fluid of the respiratory tract and their specific weight are reduced, which characterizes the benzylamine derivatives as secretolytics. 
     In addition, it is known from the literature that when the above-mentioned benzylamine derivatives are administered perorally together with an antibiotic, particularly oxytetracycline and erythromycin, or with a sulfonamide such as sulfadiazine, there is an increase in the infiltration of these substances into the bronchial secretion. The same also applies to the body&#39;s own immunoglobulins, that is, immunoglobulins which have not been administered. However, this increase in the concentration of the contents of bronchial secretion is not caused by any increased absorption from the intestines induced by the above-mentioned benzylamine derivatives or by any delay in excretion through the kidneys, since there is no detectable increase in blood level values after oral or intravenous administration. 
     OBJECTS OF THE INVENTION 
     It is an object of the invention to provide a method of improving the absorption of injected antibacterial substances or combinations. 
     It is also an object of this invention to provide a combination of an antibacterial substance or combinations and a benzylamine derivate. 
     It is a further object of this invention to provide a method of improving the absorption of an injected antibacterial substance or combination by admixing said substance with an effective amount of a benzylamine derivative of the formula ##STR2## wherein R 1  is hydroxyl in the 2- or 4-position or amino in the 2-position; 
     R 2  is hydrogen or alkyl of 1 to 3 carbon atoms; and 
     R 3  is cyclohexyl hydroxy-cyclohexyl; 
     or a non-toxic, pharmacologically acceptable acid addition salt thereof. 
     These and other objects of the invention will become apparent as the description thereof proceeds. 
     DETAILED DESCRIPTION OF THE INVENTION 
     We have discovered that when a benzylamine derivative of the formula I above or a non-toxic, pharmacologically acceptable acid addition salt thereof is administered parenterally, the absorption of an antibacterial substance or combination which has been administered parenterally into the tissues and which, on its own, does not have optimum absorbability, is speeded up. Thus, according to the invention, as a result of the higher blood levels with the same dosage of the antibacterial substance, or combination better and safer therapeutic results are obtained or--if higher blood levels are not wanted--the quantity administered can be reduced by comparison with the quantity required when the substance in question is administered by itself, and consequently a significant saving is achieved. Moreover, the problem of residues is reduced since the injection site for the antibacterial substances and combinations in question is usually the tissue, which retains measurable residues of these substances longest. 
     Therefore, the present invention relates to the novel use of the benzylamine derivatives of the formula I and non-toxic, pharmacologically acceptable acid addition salts thereof, preferably in veterinary medicine, for increasing the absorption of antibacterial substances or combinations which have been administered parenterally into the tissue and are not readily absorbed, preferably by parenteral administration of the benzylamine derivatives at the same time. 
     The preferred benzylamine derivatives of the formula I are, however, those wherein R 2  and R 3 , together with the nitrogen atom to which they are attached, form an N-methylcyclohexylamino, N-ethyl-cyclohexylamino, trans-4-hydroxycyclohexylamino, or cis-3-hydroxy-cyclohexylamino group. A particularly preferred benzylamine derivative of the formula I is N-(3,5-dibromo-2-hydroxybenzyl)-trans-4-hydroxy-cyclohexylamine or a non-toxic, pharmacologically acceptable acid addition salt thereof, especially the hydrochloride. 
     Examples of antibacterial substances used according to the invention, optionally in the form of esters or salts thereof, include the following: antibiotics of the tetracycline group, such as oxytetracycline, oxytetracycline hydrochloride, rolitetracycline or doxycycline; difficultly soluble antibiotics of the β-lactam group, such as procaine penicillin, benethamine penicillin, benzathine penicillin, the benzathine salts of oxacillin, cloxacillin, or ampicillin, and of the cephalosporins; erythromycin and derivatives thereof, such as 9-deoxy-11-deoxy-9,11-{imino-[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin, erythromycin lactobionate, erythromycin ethylsuccinate or erythromycin glucoheptonate; spiramycin or spiramycin adipate; tylosin or tylosin tartrate; oleandomycin; chloramphenicol or chloramphenicol succinate; thiamphenicol or thiamphenicol glycinate; sulfonamides or sodium salts thereof, such as sulfadiazine, sulfadoxine, sulfamethoxazole, sulfadimethoxine, sulfadimidine or sulfathiazole; a sulfonamide together with an agonist such as trimethoprim, for example, the sulfadimidine/sulfathiazole/trimethoprim combination, or the sodium salts thereof; and, optionally, the delayed-release forms thereof. 
     The invention further relates to the novel combinations which are suitable for parenteral administration into the tissue, containing a benzylamine derivative of the formula I and an antibacterial substance or combination which, by itself, does not have optimum absorbability, together with one or more conventional inert diluents or carriers, preferably those forms which are suitable for intramuscular administration. The preferred combinations are those containing (1) a benzylamine derivative of the formula I wherein R 1  is hydroxyl and R 2  and R 3 , together with the nitrogen atom to which they are attached, have the meanings defined above, preferably N-ethylcyclohexylamino, trans-4-hydroxycyclohexylamino, or cis-3-hydroxy-cyclohexylamino, and especially wherein R 1  is hydroxyl in the 2-position, and R 2  and R 3 , together with the nitrogen atom to which they are attached, are trans-4-hydroxy-cyclohexylamino, and (2) one of the above-mentioned antibacterial substances or combinations. 
     Particularly preferred embodiments of the invention are 
     (A) the combination of (1) N-(2-amino-3,5-dibromobenzyl)-N-methyl-cyclohexylamine or a non-toxic, pharmacologically acceptable acid addition salt thereof, and (2) a delayed-release oxytetracycline preparation, a delayed-release oxytetracycline hydrochloride preparation, rolitetracycline or docycycline; 
     (i) a difficultly soluble antibiotic of the β-lactam group, such as procaine penicillin, benethamine penicillin, benzathine penicillin or a benzathine salt of oxacillin, cloxacillin, ampicillin or a cephalosporin; 
     (ii) erythromycin or a derivative thereof, such as 9-deoxy-11-deoxy-9,11-{imino-[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-ethromycin, erythromycin lactobionate, erythromycin ethylsuccinate, erythromycin glucoheptonate; spiramycin, spiramycin adipate; tylosin, tylosin tartrate; oleandomycin; thiamphenicol or thiamphenicol glycinate; or 
     (iii) a sulfonamide or a sodium salt thereof, such as sulfadiazine, sulfadoxine, sulfamethoxazole, sulfadimethoxine, sulfadimidine, or sulfathiazole, or a sulfonamide combination with an agonist such as trimethoprim, for example, the sulfadimidine/sulfathiazole/trimethoprim combination; or 
     (B) the combination of (1) N-(2-amino-3,5-dibromobenzyl)-trans-4-hydroxy-cyclohexylamine or a non-toxic, pharmacologically acceptable acid addition salt thereof, and (2) 
     (i) an antibiotic of the tetracycline group, such as oxytetracycline, oxytetracycline hydrochloride, rolitetracycline or doxycycline; 
     (ii) a difficultly soluble antibiotic of the β-lactam group, such as procaine penicillin, benethamine penicillin, benzathine penicillin or a benzathine salt of oxacillin, cloxacillin, ampicillin or a cephalosporin; 
     (iii) erythromycin or one of the derivatives thereof, such as 9-deoxy-11-deoxy-9,11-{imino-[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin, erythromycin lactobionate, erythromycin ethylsuccinate, erythromycin glucoheptonate; spiramycin, spiramycin adipate; tylosin, tylosin tartrate; oleandomycin; chloramphenicol, chloramphenicol succinate; thiamphenicol or thiamphenicol glycinate; or 
     (iv) a sulfonamide or a sodium salt thereof, such as sulfadiazine, sulfadoxine, sulfamethoxazole, sulfadimethoxine, sulfadimidine or sulfathiazole, or a combination of a sulfonamide with an agonist such as trimethoprim, for example, the sulfadimidine/sulfathiazole/trimethoprim combination, or, optionally, a corresponding delayed-release form. 
     The following combinations are, however, particularly preferred: 
     (a) Combinations of (1) N-(2-amino-3,5-dibromo-benzyl)-N-methyl-cyclohexylamine or a non-toxic, pharmacologically acceptable acid addition salt thereof, or N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine or a non-toxic, pharmacologically acceptable acid addition salt thereof with (2) erythromycin, erythromycin lactobionate, erythromycin ethylsuccinate, erythromycin glucoheptonate, 9-deoxy-11-deoxy-9,11-{imino-[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin, tylosin, tylosin tartrate, spiramycin, spiramycin adipate, oleandomycin, benethamine penicillin, benzathine penicillin, ampicillin, oxacillin, cloxacillin, rolitetracycline, doxycycline, or a salt thereof; or a sulfonamide or a salt thereof, optionally in combination with trimethoprim; and 
     (b) Combinations of (1) N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine or a non-toxic, pharmacologically acceptable acid addition salt thereof with oxytetracycline or a salt thereof, chloramphenicol, chloramphenicol succinate, thiamphenicol or thiamphenicol glycinate. 
     To demonstrate the efficacy of the invention, the absorption-promoting effect of the following benzylamine derivatives: 
     A=N-(2-amino-3,5-dibromo-benzyl)-N-methyl-cyclohexylamine hydrochloride; 
     B=N-(2-amino-3,5-dibromo-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride, and 
     C=N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxycyclohexylamine hydrochloride, 
     was tested in the following manner: 
     Cattle, pigs, and sheep (with the same ten animals per group) were treated once with only the antibacterial substance or combination in question and once with the combination of the benzylamine derivative together with the same antibacterial substance or combination, administered by the intramuscular route. The two treatments were given at an interval of eight days to ensure that the substance or substances administered in the first treatment had been totally eliminated. The order of treatment varied, that is, in some cases the antibacterial substance or combination (control) was administered first and in some cases the combination including the benzylamine derivative was administered first (test group). In some cases the tests were carried out as &#34;cross-over&#34; tests, that is, on the first occasion five animals were given the antibacterial substance or combination while five animals were given the combination including the benzylamine derivative. When the test was repeated eight days later, the treatments were reversed. 
     Blood samples were taken during the day at one and two hour intervals and after 24 hours, and in some cases after 32 hours as well, and in two cases (delayed-release preparations) after 48 and 72 hours also. The levels of antibiotics or sulfonamide in the blood serum were determined using conventional microbiological methods with test pathogens specific to each substance. 
     In each case, the areas under the blood level curves obtained were compared, as an overall measurement of antibacterial activity. This comparison showed increases in blood level for the combination of benzylamine derivatives with the antibacterial substance or combination in question, compared with the control group in question, as is shown in the following table: 
     
                                           TABLE 1__________________________________________________________________________               BenzylamineAntibacterial Substance       (Dosage: mg/kg               Derivative                       Type of                            Increase in Blood Levelor Combination       of body weight)               (Dosage: mg/kg)                       Animal                            (in %, compared with control)__________________________________________________________________________Erythromycin       10      A  0.3 i.m.                       cattle                            16.1       10      C  0.6 i.m.                       cattle                            21.4       10      A  0.6 i.m.                       pig  59.1       10      A  1.2 i.m.                       pig  31.4Erythromycin derivative       10      A  1.2 i.m.                       pig  15.3       10      C  1.2 i.m.                       pig  45.4Oxytetracycline hydro-       10      C  0.6 i.m.                       cattle                            16.3chlorideDelayed-release oxy-       20      A  0.6 i.m.                       pig  109.5tetracycline preparation*       20      C  1.2 i.m.                       pig  80.0Tylosin     15      A  0.3 i.m.                       cattle                            33.0       15      C  0.6 i.m.                       cattle                            23.5Tylosin     10      A  0.6 i.m.                       pig  19.3       10      A  1.2 i.m.                       pig  30.3       10      C  0.6 i.m.                       pig  30.5       10      C  1.2 i.m.                       pig  26.1Sulfadimidine/--       24      A  0.6 i.m.                       pig  29.6Sulfathiazole/--       24      A  1.2 i.m.                       pig  25.1Trimethoprim       24      C  0.6 i.m.                       pig  29.9Combination 24      C  1.2 i.m.                       pig  20.3(10:10:4)__________________________________________________________________________ *Blood level monitored for 72 hours; after 48 hours it is 0.13 μg/ml for the control but 0.35 μg/ml for the test group; after 72 hours, it is 0.00 μg/ml for the control but still 0.19 μg/ml for the test group. 
    
     The benzylamine derivatives of the formula I and their non-toxic, pharmacologically acceptable acid addition salts are well tolerated. For example, the acute toxicity (LD 50 ) in the mouse is 
     &gt;400 mg/kg i.p. for Compound A, 
     268 mg/kg i.p. for Compound B, and 
     &gt;800 mg/kg i.p. for Compound C. 
     In view of the above-mentioned biological characteristics, the benzylamine derivatives of the formula I and their non-toxic, pharmacologically acceptable acid addition salts are, as mentioned above, suitable for improving the absorption of antibacterial substances or combinations administered parenterally into the tissue, and thus help to improve and guarantee the success of the therapy. The dosage is advantageously above 0.1 mg/kg, preferably between 0.2 and 2.0 mg/kg, while in solutions the upper limit is set by the solubility of the particular benzylamine derivative which is used. For example, in water, Compounds A to C have the following maximum solubilities: 
     
         ______________________________________Compound          Maximum Solubility______________________________________A                 0.2 to 5.0 mg/cm.sup.3B                 16.6 mg/cm.sup.3C                 0.1 to 1.0 mg/cm.sup.3______________________________________ 
    
     dependent upon the pH in the acid range. Obviously, higher concentrations can be achieved in oily carriers, dependent upon the solubility in oil of the benzylamine derivative and also upon whether the benzylamine derivative is suspended in suitable carriers in which it is insoluble or not sufficiently soluble. 
     Moreover, the benzylamine derivative is preferably administered simultaneously with a therapeutic dose of the antibacterial substance or combination which is to be used. Examples of individual doses include the following: 
     
                       TABLE 2______________________________________Active Substance    Dose______________________________________oxytetracycline     5 to 30     mg/kgrolitetracycline    15 to 50    mg/kgdoxycycline         2 to 5      mg/kgerythromycin        5 to 20     mg/kg9-deoxy-11-deoxy-9,11-{imino-               5 to 20     mg/kg[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycinspiramycin          10 to 50    mg/kgtylosin             5 to 20     mg/kgchloramphenicol     10 to 50    mg/kgthiamphenicol       10 to 50    mg/kgsulfadiazine        15 to 50    mg/kgsulfadiazine/sulfathiazole/-               15 to 30    mg/kgtrimethoprimsulfadoxin/trimethoprim               15 to 30    mg/kgprocaine penicillin 2,000 to 20,000                           I.U./kgbenzathine penicillin               6,000 to 25,000                           I.U./kgampicillin          2 to 15     mg/kgoxacillin           5 to 15     mg/kgcloxacillin         5 to 15     mg/kgoxytetracycline hydrochloride               2 to 25     mg/kg______________________________________ 
    
     Examples of suitable forms for administration include injectable preparations of an aqueous, water-miscible or oily nature in which the antibacterial substances in question are dissolved or suspended in the desired concentration. The same also applies to the benzylamine derivatives or the salts thereof, depending on their solubility, while the same preparation may contain one substance in solution and the other in suspension. In those cases where an aqueous solution is desired but is not practicable due to insufficient stability, such as of the antibiotic, the injectable combination is prepared shortly before administration by dissolving or suspending the dry substance in the solvent containing the benzylamine derivative. 
     The benzylamine derivatives of the formula I and their non-toxic, pharmacologically acceptable acid addition salts are known; see, for example, U.S. Pat. Nos. 3,336,308, 3,536,713 and 4,113,777. 
     The compounds of the formula I may be obtained in the form of their non-toxic, pharmacologically acceptable acid addition salts after reaction with inorganic or organic acids. Suitable acids include, for example, hydrochloric, hydrobromic, sulfuric, methylsulfuric, phosphoric, tartaric, fumaric, citric, maleic, succinic, gluconic, malic, p-toluenesulfonic, methanesulfonic and amidosulfonic acid. 
     The following examples illustrate the present invention and will enable others skilled in the art to understand it more completely. It should be understood, however, that the invention is not limited solely to the particular examples given below. 
    
    
     EXAMPLES 
     EXAMPLE 1 
     Two-compartment preparation containing 9-deoxy-11-deoxy-9,11-{imino-[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin lactobionate (antibiotic) and N-(2-amino-3,5-dibromo-benzyl)-N-methyl-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Compostion______________________________________(a)     Dry ampule   Antibiotic           715.0  mg(b)     Solution ampule   Active substance     75.0   mg   Tartaric acid        37.5   mg   Glycerin polyethyleneglycol                        250.0  mg   oxystearate   Glucose              200.0  mg   Water for injection q.s. ad                        5.0    ml______________________________________ 
    
     Method 
     To prepare the dry ampule, the antibiotic is dissolved in water for injection, sterilized, and freed from pyrogens by means of a suitable filter system, possibly by use of pyrogen adsorption layers, and then transferred under aseptic conditions, in the desired dosages, into 10 ml injection vials which have been cleaned and sterilized. These vials are freeze-dried in the usual way. 
     Next, to prepare the solution ampule, the active substance and excipients are successively dissolved in water for injection purposes, filtering is carried out in the same way as with the dry ampule solution, and the resulting solution is transferred into 5 ml ampules. For sterilization, the fused ampules and the injection vials, sealed with rubber stoppers and crimped aluminum caps, are heated at 121° C. for 20 minutes. 
     EXAMPLE 2 
     Two-compartment preparation containing 9-deoxy-11-deoxy-9,11-{imino-[2-(methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin lactobionate (antibiotic) and N-(2-amino-3,5-dibromobenzyl)-N-methyl-cyclohexylamine hydrochloride (aqueous solution) (active substance) 
     
         ______________________________________Composition______________________________________(a)    Dry ampule  Atibiotic            3575.0  mg(b)    Solution ampule  Active substance     375.0   mg  Tartaric acid        187.5   mg  Glycerin polyethyleneglycol                       1250.0  mg  oxystearate          1250.0  mg  Glucose              1000.0  mg  Water for injection q.s. ad                       25.0    ml______________________________________ 
    
     Method 
     The ampules (a) and (b) are prepared by a procedure analogous to that of Example 1. However, the active substance is transferred into 25 ml or 30 ml injection vials. 
     EXAMPLE 3 
     Oily suspension containing 9-deoxy-11-deoxy-9,11-{imino-[-2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin (antibiotic) and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Antibiotic            500.0  mgActive substance      100.0  mgBenzyl alcohol        50.0   mgNeutral oil q.s. ad   5.0    ml______________________________________ 
    
     Method 
     The antibiotic and active substance are dissolved or suspended in a mixture of the two excipients, while heating, and the resulting mixture is transferred under aseptic conditions into 5 ml-ampules which have been cleaned and sterilized. 
     EXAMPLE 4 
     Oily suspension containing 9-deoxy-11-deoxy-9,11-{imino-[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin (antibiotic) and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Antibiotic            2500.0  mgActive substance      500.0   mgBenzyl alcohol        250.0   mgNeutral oil q.s. ad   25.0 ml______________________________________ 
    
     Method 
     The antibiotic and the active substance are dissolved or suspended in a mixture of the two excipients, while heating, and the resulting mixture is transferred, under aseptic conditions, into 25 ml injection vials which have been cleaned and sterilized. 
     EXAMPLE 5 
     Two-compartment preparation containing 9-deoxy-11-deoxy-9,11-{imino-[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin lactobionate (antibiotic) and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (aqueous suspension) (active substance) 
     
         ______________________________________Composition______________________________________(a)   Dry ampule Antibiotic              715.0  mg(b)   Ampule containing suspension/solution Active substance        100.0  mg Polyethyleneglycol stearate                         1.0    mg Sorbitol                250.0  mg Methyl hydroxyethyl cellulose                         15.0   mg Water for injection q.s. ad                         5.0    ml______________________________________ 
    
     Method 
     To prepare the dry ampule, the active substance is dissolved in water for injection, sterilized, freed from pyrogens by means of a suitable filter system, possibly by use of pyrogen adsorption layers, and then transferred under aseptic conditions, in the desired dosages, into 10 ml injection vials which have been cleaned and sterilized. These vials are freeze-dried in the usual way. 
     Next, to prepare the ampules of suspension/solution, the excipients are dissolved in water for injection purposes, and the solution is filtered to sterilize it and to remove any pyrogens. The active substance is suspended in this solution under aseptic conditions, and the suspension is transferred, while stirring, into 5 ml-ampules which have been cleaned and sterilized. 
     EXAMPLE 6 
     Two-compartment preparation containing 9-deoxy-11-deoxy-9,11-{imino-[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin lactobionate (antibiotic) and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (aqueous suspension) (active substance) 
     
         ______________________________________Composition______________________________________(a)   Dry ampule Antibiotic              3575.0  mg(b)   Ampule containing suspension/solution Active substance        500.0   mg Polyethyleneglycol stearate                         5.0     mg Sorbitol                1250.0  mg Methyl hydroxyethyl cellulose                         75.0    mg Water for injection q.s. ad                         25.0    ml______________________________________ 
    
     Method 
     The ampules (a) and (b) are prepared by a procedure analogous to that of Example 5. However, the components are transferred into 25 ml and 30 ml injection vials, respectively. 
     EXAMPLE 7 
     Injectable solution containing oxytetracycline hydrochloride (antibiotic) and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine (active substance) 
     
         ______________________________________Composition______________________________________Antibiotic           5.0      gmActive substance     0.05-0.8 gmMagnesium oxide      0.45     gmpH adjuster          1.0      gmAntioxidants         0.2      gmSolketal ®       15.0     gm1,2-Propyleneglycol  74.0     gmWater for injection q.s. ad                100.0    ml______________________________________ 
    
     Method 
     In a suitable vessel, the antibiotic is dissolved in the corresponding quantity of water, and 1,2-propyleneglycol and then magnesium oxide are added. At the same time, a solution of Solketal® and active substance in the corresponding quantity of 1,2-propyleneglycol is prepared. The two solutions are combined, and a solution of the antioxidants in a small amount of water is added thereto. The desired pH value is obtained by adding the pH adjuster. The solution is prepared and transferred into vials in a nitrogen atmosphere and under aseptic conditions. The solution must be sterilized by filtration. 
     EXAMPLE 8 
     Aqueous suspension containing chloramphenicol or thiamphenicol (antibiotic) and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Antibiotic             20.0     gmActive substance       0.05-2.5 gmSuspension stabilizers 1.6      gmEmulsifier             2.0      gmCitric acid            1.0      gmAntifoaming agent      0.2      gmMethiolate             0.005    gm1 N Sodium hydroxide solution                  3.25     gmWater for injection q.s. ad                  100.0    ml______________________________________ 
    
     Method 
     Merthiolate and citric acid are dissolved in about one-third of the quantity of water and placed in a suitable vessel. The active substance, suspension stabilizers, and antifoaming agent are successively added to this solution and dissolved or suspended therein. 
     The emulsifier is dissolved in about one-third of the quantity of water, while heating, and added thereto. A suspension of antibiotic in water is added, with stirring, while the homogeneous suspension is adjusted to the desired pH value with 1N NaOH, having been diluted to 100 ml with the remaining water. All the excipients and active substances or solutions thereof are sterilized before use. The preparation must be made up and bottled under aseptic conditions. 
     EXAMPLE 9 
     Injection solution containing tylosin and N-(2-amino-3,5-dibromobenzyl)-N-methyl-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Tylosin               50.0    mgActive substance      0.5-6.0 mg1,2-Propyleneglycol   0.5     mlBenzyl alcohol        0.04    mlHydrochloric acid q.s. ad                 pH 4Water for injection q.s. ad                 1.0     ml______________________________________ 
    
     Method 
     The active substance is dissolved in 90 ml of a suitable mixture of 1,2-propyleneglycol and water, with stirring and ultrasonic treatment, in a current of nitrogen. Tylosin is added and dissolved to form a clear solution. After the addition of the benzyl alcohol, the mixture is adjusted to the desired pH with 1N HCl and then diluted to 100 ml with water. The solution must be prepared and bottled under aseptic conditions. 
     EXAMPLE 10 
     Injection solution containing tylosin and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Tylosin               50.0    mgActive substance      0.5-6.0 mg1,2-Propyleneglycol   0.5     mlBenzyl alcohol        0.04    mlHydrochloric acid q.s. ad                 pH 4Water for injection q.s. ad                 1.0     ml______________________________________ 
    
     Method 
     The solution is prepared by using a procedure analogous to that of Example 9. 
     EXAMPLE 11 
     Oil suspension containing erythromycin and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Erythromycin           50.0     mgActive substance       0.5-25.0 mgSodium diotylsulfosuccinate                  2.0      mgNeutral oil q.s. ad    1.0      ml______________________________________ 
    
     Method 
     Sodium dioctylsulfosuccinate is dissolved in the corresponding quantity of neutral oil while heating and stirring. After the solution has cooled to room temperature, erythromycin is dissolved therein, and active substance of a suitable particle size is added. The resulting suspension is homogenized with a suitable stirrer and bottled under aseptic conditions. 
     EXAMPLE 12 
     Suspension containing erythromycin and N-(2-amino-3,5-dibromo-benzyl)-N-methyl-cyclohexylamine (active substance) 
     
         ______________________________________Composition______________________________________Erythromycin        50.0      mgActive substance    0.5-25.0  mgNeutral oil         q.s. ad 1.0                         ml______________________________________ 
    
     Method 
     The suspension is prepared using a procedure analogous to that of Example 11. 
     EXAMPLE 13 
     Injection solution containing trimethoprim, sulfadimidine, sulfathiazole, and N-(2-amino-3,5-dibromo-benzyl)-N-methyl-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Trimethoprim        40.0      mgSulfadimidine       100.0     mgSulfathiazole       100.0     mgActive substance    0.5-6.0   mgGlycerol formal     q.s. ad 1.0                         ml______________________________________ 
    
     Method 
     The active substance is dissolved in glycerol formal while stirring and in a current of nitrogen. Then, trimethoprim, sulfadimidine and sulfathiazole are successively dissolved therein, while stirring. The solution is then diluted with the remaining glycerol formal. The preparation must be made up and bottled under aseptic conditions and in the absence of direct light. 
     EXAMPLE 14 
     Injection solution containing trimethoprim, sulfadimidine, sulfathiazole and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Trimethoprim        40.0      mgSulfadimidine       100.0     mgSulfathiazole       100.0     mgActive substance    0.5-15.0  mgGlycerin formal     q.s. ad 1.0                         ml______________________________________ 
    
     Method 
     The solution is prepared by using a procedure analogous to that of Example 13. 
     EXAMPLE 15 
     Injection solution containing spiramycin and N-(2-amino-3,5-dibromo-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Active substance     0.5-6.0   mgSpiramycin           50.0      mg1,2-Propyleneglycol  0.5       mlWater for injection  q.s. ad 1.0                          ml1 N Hydrochloric acid                q.s. ad pH                          3.8______________________________________ 
    
     Method 
     The active substance is dissolved, while stirring, in a mixture of 1,2-propyleneglycol and water in a current of nitrogen, and the spiramycin is dissolved in the solution. The solution is adjusted to the desired pH with 1N HCl and diluted with water. The preparation must be made up and bottled under aseptic conditions. 
     EXAMPLE 16 
     Injection solution containing spiramycin and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine 
     
         ______________________________________Composition______________________________________Active substance    0.5-15.0  mgSpiramycin          50.0      mgGlycofurol          q.s. ad 1.0                         ml______________________________________ 
    
     Method 
     A solution of spiramycin in glycofurol is prepared in a current of nitrogen and then the active substance is added to the solution in small portions, again in a current of nitrogen, and dissolved therein. The solution is bottled under aseptic conditions and in an atmosphere of nitrogen. 
     EXAMPLE 17 
     Two-compartment preparation containing 9-deoxy-11-deoxy-9,11-{imino-[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin lactobionate (antibiotic) and N-(2-amino-3,5-dibromo-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________(a)   Dry ampule. Antibiotic           715.0     mg(b)   Solution ampule. Active substance     75.0      mg Tartaric acid        37.5      mg Glycerin polyethyleneglycol                      250.0     mg oxystearate Glucose              200.0     mg Water for injection  q.s. ad 5.0                                ml______________________________________ 
    
     Method 
     The ampules (a) and (b) are prepared by a procedure analogous to that of Example 1. 
     EXAMPLE 18 
     Oily suspension containing 9-deoxy-11-deoxy-9,11-{imino-[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin (antibiotic) and N-(2-amino-3,5-dibromo-benzyl)-N-methyl-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Antibiotic             200.0     mgActive substance       2.0-20.0  mg4-Chloro-m-cresol      2.0       mgAluminum monostearate  10.0      mgNeutral oil (e.g. Miglyol ® 812                  q.s. ad 1.0                            mlavailable from Dynamit Nobel Co.)______________________________________ 
    
     Preparation 
     The aluminum monostearate is dispersed in the corresponding quantity of neutral oil, while stirring and heating. After the mixture has cooled to room temperature, first the 4-Chloro-m-cresol, then the antibiotic and the active substance in a suitable particle size are added and dissolved or suspended while stirring. The resulting suspension is filled into ampules under aseptic conditions. 
     EXAMPLE 19 
     Oily suspension containing 9-deoxy-11-deoxy-9,11-{imino-[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin lactobionate (antibiotic) and N-(2-amino-3,5-dibromo-benzyl)-N-methyl-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Antibiotic             285.8     mgActive substance       2.0-20.0  mg4-Chloro-m-cresol      2.0       mgAluminum monostearate  10.0      mgNeutral oil (e.g. Miglyol ® 812)                  q.s. ad 1.0                            ml______________________________________ 
    
     Preparation 
     Analogous to Example 18. 
     EXAMPLE 20 
     Oily suspension containing 9-deoxy-11-deoxy-9,11-{imino-[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin lactobionate (antibiotic) and N-(2-amino-3,5-dibromo-benzyl)-N-methyl-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Antibiotic             143.0     mgActive substance       2.0-20.0  mg4-Chloro-m-cresol      2.0       mgAluminum monostearate  10.0      mgNeutral oil (e.g. Miglyol ® 812)                  q.s. ad 1.0                            ml______________________________________ 
    
     Preparation 
     Analogous to Example 18. 
     EXAMPLE 21 
     Oily suspension containing 9-deoxy-11-deoxy-9,11-{imino-[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin (antibiotic) and N-(2-amino-3,5-dibromo-benzyle-N-methyl-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Antibiotic             100.0     mgActive substance       2.0-20.0  mg4-Chloro-m-cresol      2.0       mgAluminum monostearate  10.0      mgNeutral oil (e.g. Miglyol ® 812)                  q.s. ad 1.0                            ml______________________________________ 
    
     Preparation 
     Analogous to Example 18. 
     EXAMPLE 22 
     Oily suspension containing 9-deoxy-11-deoxy-9,11-{imino-[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin (antibiotic) and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Antibiotic             200.0     mgActive substance       3.0-20.0  mg4-Chloro-m-cresol      2.0       mgAluminum monostearate  10.0      mgNeutral oil (e.g. Miglyol ® 812)                  q.s. ad 1.0                            ml______________________________________ 
    
     Preparation 
     Analogous to Example 18. 
     EXAMPLE 23 
     Oily suspension containing 9-deoxy-11-deoxy-9,11-{imino-[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin lactobionate (antibiotic) and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Antibiotic             285.8     mgActive substance       3.0-20.0  mg4-Chloro-m-cresol      2.0       mgAluminum monostearate  10.0      mgNeutral oil (e.g. Miglyol ® 812)                  q.s. ad 1.0                            ml______________________________________ 
    
     Preparation 
     Analogous to Example 18. 
     EXAMPLE 24 
     Oily suspension containing 9-deoxy-11-deoxy-9,11-{imino-[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin lactobionate (antibiotic) and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Antibiotic             143.0     mgActive substance       3.0-20.0  mg4-Chloro-m-cresol      2.0       mgAluminum monostearate  10.0      mgNeutral oil (e.g. Miglyol ® 812)                  q.s. ad 1.0                            ml______________________________________ 
    
     Preparation 
     Analogous to Example 18. 
     EXAMPLE 25 
     Oily suspension containing 9-deoxy-11-deoxy-9,11-{imino-[2-(2-methoxyethoxy)-ethylidene]-oxy}-(9F)-erythromycin (antibiotic) and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Antibiotic             100.0     mgActive substance       3.0-20.0  mg4-Chloro-m-cresol      2.0       mgAluminum monostearate  10.0      mgNeutral oil (e.g. Miglyol ® 812)                  q.s. ad 1.0                            ml______________________________________ 
    
     Preparation 
     Analogous to Example 18. 
     EXAMPLE 26 
     Oily suspension containing oxytetracyclin hydrochloride (antibiotic) and N-(2-amino-3,5-dibromo-benzyl)-N-methyl-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Antibiotic             200.0     mgActive substance       2.0-20.0  mg4-Chloro-m-cresol      2.0       mgSodium dioctylsulfosuccinate                  0.7       mgNeutral oil (e.g. Miglyol ® 812)                  q.s. ad 1.0                            ml______________________________________ 
    
     Preparation 
     Production takes place under aseptic conditions and constant gas load. Sodium dioctylsulfosuccinate and 4-Chloro-m-cresol are dissolved in a suitable quantity of neutral oil while stirring. The solution is sterilized by filtration. Oxytetracyclin x HCl and the active substance are added to another suitable quantity of neutral oil while stirring, and the resulting suspension is milled to micronize the antibiotic particles. Solution and suspension are then combined, homogenized and filled into ampules under sterile conditions. 
     EXAMPLE 27 
     Oily suspension containing oxytetracyclin hydrochloride (antibiotic) and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Antibiotic             200.0     mgActive substance       3.0-20.0  mg4-Chloro-m-cresol      2.0       mgSodium dioctylsulfosuccinate                  0.7       mgNeutral oil (e.g. Miglyol ® 812) q.s. ad                  1.0       ml______________________________________ 
    
     Preparation 
     Analogous to Example 26. 
     EXAMPLE 28 
     Sterile solid for injection containing ampicillin and N-(2-amino-3,5-dibromo-benzyl)-N-methyl-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Ampicillin × 3 H.sub.2 O                 173.0 mgActive substance      4.0-40.0 mg______________________________________ 
    
     Solvent ampule 
     
         ______________________________________Composition______________________________________Tartaric acid           2.0-8.0   mgSodium hydroxide        0.5       mgPolyoxyethylene hydrogenated castor oil                   20.0      mgDistilled water q.s. ad 1.0       ml______________________________________ 
    
     Preparation 
     The antibiotic and the active substance are filled under sterile conditions into injection vials which then are sealed with a pierceable rubber closure and aluminum cap. 
     The solvent is prepared in an appropriate volume by dissolving first polyoxyethylene hydrogenated castor oil, while stirring, in a suitable amount of WfI (water for injection), then adding sodium hydroxide and tartaric acid. After adjustment of total volume with WfI, the solution is filtered and filled into ampules. The ampules are sealed and sterilized in an autoclave. 
     EXAMPLE 29 
     Sterile solid for injection containing ampicillin and N-(2-amino-3,5-dibromo-benzyl)-N-methyl-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Ampicillin × 3 H.sub.2 O                1,730.0 mgActive substance     40-400.0 mg______________________________________ 
    
     Solvent ampules 
     
         ______________________________________Composition______________________________________Tartaric acid           20.0-80.0 mgSodium hydroxide        5.0       mgPolyoxyethylene hydrogenated castor oil                   200.0     mg4-Chloro-m-cresol       20.0      mgDistilled water q.s. ad 10.0      ml______________________________________ 
    
     Preparation 
     Analogous to Example 28. 
     EXAMPLE 30 
     Oily suspension containing ampicillin and N-(2-amino-3,5-dibromo-benzyl)-N-methyl-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Ampicillin × 3 H.sub.2 O                  173.0     mgActive substance       4.0-40.0  mg4-Chloro-m-cresol      2.0       mgSodium dioctylsulfosuccinate                  0.7       mgNeutral oil (e.g. Miglyol ® 812) q.s. ad                  1.0       ml______________________________________ 
    
     Preparation 
     Analogous to Example 26. 
     EXAMPLE 31 
     Sterile solid for injection containing ampicillin and N-(2-amino-3,5-dibromo-benzyl)-N-methyl-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Ampicillin × 3 H.sub.2 O                 230.0 mgActive substance      4.0-40.0 mg______________________________________ 
    
     Solvent ampule 
     
         ______________________________________Composition______________________________________Tartaric acid           2.0-8.0   mgSodium hydroxide        0.5       mgPolyoxyethylene hydrogenated castor oil                   20.0      mgDistilled water q.s. ad 1.0       ml______________________________________ 
    
     Preparation 
     Analogous to Example 28. 
     EXAMPLE 32 
     Oily suspension containing ampicillin and N-(2-amino-3,5-dibromo-benzyl)-N-methyl-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Ampicillin × 3 H.sub.2 O                  230.0     mgActive substance       4.0-40.0  mg4-Chloro-m-cresol      2.0       mgSodium dioctylsulfosuccinate                  1.0       mgNeutral oil (e.g. Miglyol ® 812) q.s. ad                  1.0       ml______________________________________ 
    
     Preparation 
     Analogous to Example 26. 
     EXAMPLE 33 
     Sterile solid for injection containing benzathine ampicillin and N-(2-amino-3,5-dibromo-benzyl)-N-methyl-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Benzathine ampicillin 276.5 mgActive substance      4.0-40.0 mg______________________________________ 
    
     Solvent ampule 
     
         ______________________________________Composition______________________________________Tartaric acid           2.0-8.0   mgSodium hydroxide        0.5       mgPolyoxyethylene hydrogenated castor oil                   30.0      mgDistilled water q.s. ad 1.0       ml______________________________________ 
    
     Preparation 
     Analogous to Example 28. 
     EXAMPLE 34 
     Oily suspension containing benzathine ampicillin, ampicillin sodium and N-(2-amino-3,5-dibromo-benzyl)-N-methyl-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Benzathine ampicillin  276.5     mgAmpicillin sodium      21.3      mgActive substance       4.0-40.0  mg4-Chloro-m-cresol      2.0       mgSodium dioctylsulfosuccinate                  1.5       mgNeutral oil (e.g. Miglyol ® 812) q.s. ad                  1.0       ml______________________________________ 
    
     Preparation 
     Analogous to Example 26. 
     EXAMPLE 35 
     Sterile solid for injection containing ampicillin and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Ampicillin × 3 H.sub.2 O                 173.0 mgActive substance      6.0-24.0 mg______________________________________ 
    
     Solvent ampule 
     
         ______________________________________Composition______________________________________Tartaric acid           2.0-8.0   mgSodium hydroxide        0.5       mgPolyoxyethylene hydrogenated castor oil                   20.0      mgDistilled water         q.s. ad 1.0                             ml______________________________________ 
    
     Preparation 
     Analogous to Example 28. 
     EXAMPLE 36 
     Oily suspension containing ampicillin and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Ampicillin × 3 H.sub.2 O                  173.0     mgActive substance       6.0-24.0  mg4-Chloro-m-cresol      2.0       mgSodium dioctylsulfosuccinate                  0.7       mgNeutral oil (e.g. Miglyol ® 812)                  q.s. ad 1.0                            ml______________________________________ 
    
     Preparation 
     Analogous to Example 26. 
     EXAMPLE 37 
     Sterile solid for injection containing ampicillin and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Ampicillin × 3 H.sub.2 O                 230.0 mgActive substance      6.0-4.0 mg______________________________________ 
    
     Solvent ampule 
     
         ______________________________________Composition______________________________________Tartaric acid           2.0-8.0   mgSodium hydroxide        0.5       mgPolyoxyethylene hydrogenated castor oil                   20.0      mgDistilled water         q.s. ad 1.0                             ml______________________________________ 
    
     Preparation 
     Analogous to Example 28. 
     EXAMPLE 38 
     Oily suspension containing ampicillin and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Ampicillin × 3 H.sub.2 O                  230.0     mgActive substance       6.0-24.0  mg4-Chloro-m-cresol      2.0       mgSodium dioctylsulfosuccinate                  1.0       mgNeutral oil (e.g. Miglyol  ® 812)                  q.s. ad 1.0                            ml______________________________________ 
    
     Preparation 
     Analogous to Example 26. 
     EXAMPLE 39 
     Sterile solid for injection containing benzathine ampicillin and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Benzathine ampicillin 276.5 mgActive substance      6.0-24.0 mg______________________________________ 
    
     Solvent ampule 
     
         ______________________________________Composition______________________________________Tartaric acid           2.0-8.0   mgSodium hydroxide        0.5       mgPolyoxyethylene hydrogenated castor oil                   30.0      mgDistilled water         q.s. ad 1.0                             ml______________________________________ 
    
     Preparation 
     Analogous to Example 28. 
     EXAMPLE 40 
     Oily suspension containing benzathine ampicillin, ampicillin sodium and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Benzathine ampicillin  276.5     mgAmpicillin sodium      21.3      mgActive substance       6.0-24.0  mg4-Chloro-m-cresol      2.0       mgSodium dioctylsulfosuccinate                  1.5       mgNeutral oil (e.g. Miglyol ® 812)                  q.s. ad 1.0                            ml______________________________________ 
    
     Preparation 
     Analogous to Example 26. 
     EXAMPLE 41 
     Sterile solid for injection containing ampicillin and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Ampicillin × 3 H.sub.2 O                 173.0 mgActive substance      6.0-40.0 mg______________________________________ 
    
     Solvent ampule 
     
         ______________________________________Composition______________________________________Tartaric acid           2.0-8.0   mgSodium hydroxide        0.5       mgPolyoxyethylene hydrogenated castor oil                   20.0      mgDistilled water         q.s. ad 1.0                             ml______________________________________ 
    
     Preparation 
     Analogous to Example 28. 
     EXAMPLE 42 
     Oily suspension containing ampicillin and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Ampicillin × 3 H.sub.2 O                  173.0     mgActive substance       6.0-40.0  mg4-Chloro-m-cresol      2.0       mgSodium dioctylsulfosuccinate                  0.7       mgNeutral oil (e.g. Miglyol ® 812)                  q.s. ad 1.0                            ml______________________________________ 
    
     Preparation 
     Analogous to Example 26. 
     EXAMPLE 43 
     Sterile solid for injection containing ampicillin and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Ampicillin × 3 H.sub.2 O                 230.0 mgActive substance      6.0-40.0 mg______________________________________ 
    
     Solvent ampule 
     
         ______________________________________Composition______________________________________Tartaric acid           2.0-8.0   mgSodium hycroxide        0.5       mgPolyoxyethylene hydrogenated castor oil                   20.0      mgDistilled water         q.s. ad 1.0                             ml______________________________________ 
    
     Preparation 
     Analogous to Example 28. 
     EXAMPLE 44 
     Oily suspension containing ampicillin and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride 
     
         ______________________________________Composition______________________________________Ampicillin × 3 H.sub.2 O                  230.0     mgActive substance       6.0-40.0  mg4-Chloro-m-cresol      2.0       mgSodium dioctylsulfosuccinate                  1.0       mgNeutal oil (e.g. Miglyol ® 812)                  q.s. ad 1.0                            ml______________________________________ 
    
     Preparation 
     Analogous to Example 26. 
     EXAMPLE 45 
     Sterile solid for injection containing benzathine ampicillin and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Benzathine ampicillin 276.5 mgActive substance      6.0-40.0 mg______________________________________ 
    
     Solvent ampule 
     
         ______________________________________Composition______________________________________Tartaric acid           2.0-8.0   mgSodium hydroxide        0.5       mgPolyoxyethylene hydrogenated castor oil                   30.0      mgDistilled water q.s. ad 1.0       ml______________________________________ 
    
     Preparation 
     Analogous to Example 28. 
     EXAMPLE 46 
     Oily suspension containing benzathine ampicillin, ampicillin sodium and N-(3,5-dibromo-2-hydroxy-benzyl)-trans-4-hydroxy-cyclohexylamine hydrochloride (active substance) 
     
         ______________________________________Composition______________________________________Benzathine ampicillin  276.5     mgAmpicillin sodium      21.3      mgActive substance       6.0-40.0  mg4-Chloro-m-cresol      2.0       mgSodium dioctylsulfosuccinate                  1.5       mgNeutral oil (e.g. Miglyol ® 812) q.s. ad                  1.0       ml______________________________________ 
    
     Preparation 
     Analogous to Example 26. 
     Any one of the other compounds embraced by formula I or a non-toxic, pharmacologically acceptable acid addition salt thereof may be substituted for the particular active substance in Examples 18 through 46. Likewise, the amount of antibiotic and active substance in these illustrative examples may be varied to achieve the dosage ranges set forth above, and the amounts and nature of the inert pharmaceutical carrier ingredients may be varied to meet particular requirements. 
     While the present invention has been illustrated with the aid of certain specific embodiments thereof, it will be readily apparent to others skilled in the art that the invention is not limited to these particular embodiments, and that various changes and modifications may be made without departing from the spirit of the invention or the scope of the appended claims.